Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

Medexus Pharmaceuticals (TSX:MDP) has revealed that the U.S. Food and Drug Administration has extended the review period for ...

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

Medexus Pharmaceuticals Inc. Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – September 16, 2024) – Medexus ...

The treatment landscape of chronic lymphocytic leukaemia (CLL) was transformed when the small molecule drug ibrutinib ...